title: Treating gliomas with glucocorticoids: from bedside to bench.
abstract: Glucocorticoids are used in the treatment of gliomas to decrease tumour-associated oedema and to reduce the risk of acute encephalopathy associated with radiotherapy. However, the mechanisms by which glucocorticoids work are still largely unknown. In this paper, we survey the experimental and clinical evidence for the effects of glucocorticoids on tumour cell proliferation, apoptosis and sensitivity to chemotherapy, angiogenesis and vascular permeability. We then review current guidelines on the choice of molecule, dose and duration of glucocorticoid treatment for gliomas.
authors.affiliation: Laboratoire de Biologie des Tumeurs et du Développement, Université de Liège, Liège, Belgium.
authors.forename: Caroline
authors.initials: C
authors.lastname: Piette
authors.forename: Carine
authors.initials: C
authors.lastname: Munaut
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Foidart
authors.forename: Manuel
authors.initials: M
authors.lastname: Deprez
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy*; D002199:Capillary Permeability / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D005910:Glioma / Q000188:drug therapy*; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy
chemical_list: D005938:Glucocorticoids